Drug combo shrinks melanoma tumors before surgery, study shows
NCT ID NCT02231775
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study tested two targeted drugs, dabrafenib and trametinib, given before and after surgery in 58 people with stage III melanoma that has a BRAF gene mutation. The goal was to shrink tumors before surgery and kill any remaining cancer cells afterward. The approach aims to improve the chance of staying cancer-free and reduce the amount of tissue removed during surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common heart drug boost immunotherapy against melanoma?
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- New drug combo aims to boost immune attack on melanoma
- New combo therapy offers hope for melanoma patients who failed standard treatment
- Two-Drug combo shows promise against tough skin cancer
- Double immune attack: new combo therapy shows promise for tough melanoma